Received: 9 June 2021
Accepted: 3 November 2021
First Online: 19 November 2021
: The methods were carried out in accordance with relevant guidelines and regulations. The American Psychiatric Association Institutional Review Board deemed the study minimal risk, waived the requirement for informed consent, and approved the methods of the study.
: De-identified program-level data was utilized from each program.
: ROC has received research support from Otsuka, Lundbeck, and Roche. He is a consultant to the American Psychiatric Association and Saladax Biomedical. JMM reports receiving speaking or advising fees from Acadia Pharmaceuticals, Alkermes, AbbVie, Intra-Cellular Therapies, Neurocrine, Noven, Otsuka America, Inc., and Sunovion Pharmaceuticals. The remaining authors declare that they have no completing interests.